Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 04, 2015 12:43 PM ET


Company Overview of Wyeth Pharmaceuticals, Inc.

Company Overview

Wyeth Pharmaceuticals, Inc. develops, manufactures, and markets pharmaceutical products to treat cardiovascular and gastrointestinal diseases, infectious diseases, cancer, women's health concerns, and depression. It offers antidepressant Effexor, estrogen replacement therapy Premarin, and acid reflux disease drug Protonix; XYNTHA, a recombinant factor VIII product for the control and prevention of bleeding episodes and surgical prophylaxis; and Prevnar 13, a pneumococcal 13-valent conjugate vaccine. The company also offers vaccines and nutritional products, including infant formulas and adult supplements. It serves health care professionals and patients in the United States and Canada. The c...

500 Arcola Road

Collegeville, PA 19426

United States

Founded in 2002





Key Executives for Wyeth Pharmaceuticals, Inc.

Chief Financial Officer and Executive Vice President
Age: 61
President of Europe, Middle East, Africa & Canada
Age: 57
Executive Vice President
Age: 67
Executive Vice President
Executive Vice President of Vaccines Research & Development
Age: 62
Compensation as of Fiscal Year 2015.

Wyeth Pharmaceuticals, Inc. Key Developments

Attorneys General Reaches Settlement Agreement with Wyeth Pharmaceuticals Inc

Texas Attorney General Greg Abbott and 41 other state attorneys general secured a $35 million agreement with Wyeth Pharmaceuticals Inc. The agreement resolves a multistate investigation against Wyeth for unlawfully promoting its immunosuppressive drug Rapamune. Under the settlement agreement, Pfizer must pay the State of Texas a total of $2.387 million. The agreement orders $1.591 million of the settlement funds to be disbursed to the General Revenue or the Supreme Court Judicial Fund, as appropriate, pursuant to Texas Government Code Sec. 402.007. The remaining funds will reimburse the State's legal fees.

Similar Private Companies By Industry

Company Name Region
Pentech Pharmaceuticals, Inc. United States
Ayerst-Wyeth Pharmaceuticals Incorporated United States
Searle, Ltd. United States
GeneraMedix, Inc. United States
BattelleCRO, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Wyeth Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at